Medifast repackages a decade-old coaching trial to launch its Trilivy brand
The 98% lean-mass and 14% visceral-fat figures Medifast used to introduce Trilivy trace to a 198-person trial that finished in 2017 and reported its primary weight-change endpoint without a disclosed result.
Executive Summary
- Medifast used figures from a completed, not-applicable-phase behavioral weight-loss trial to launch a new brand and product system, rather than disclosing a new clinical readout.
- The trial's registered primary measure was body weight change, but the company's public figures center on lean-mass retention and visceral-fat reduction, secondary body-composition measures, leaving the primary result unaddressed in the materials reviewed.
- The company's own promotional framing draws on relative comparisons and emphasizes results not identified as the trial's primary analysis, a pattern that warrants reading the absolute figures independently before accepting the marketing framing.
- Medifast's coached-diet approach sits in an obesity treatment landscape now dominated by GLP-1 receptor agonists in Phase 3 and Phase 4 testing, a mechanistically distinct category with a different efficacy bar.
The launch
Medifast, Inc. introduced Trilivy, a coaching and meal-replacement system replacing its OPTAVIA brand, in a press release built around a completed clinical study. The release states that participants on the Optimal Weight 5 & 1 Plan retained 98% of lean mass and achieved a 14% reduction in visceral fat over 16 weeks, attributing the figures to the trial the company calls Arterburn et al. Chief Executive Officer Nick Johnson said the launch reflects the company's evolution toward a broader metabolic-health message rather than a narrower weight-loss pitch. The cited study is NCT02835092, a randomized, open-label, three-arm trial run by Medifast that enrolled 198 adults with a body mass index between 27 and 42 and completed on February 1, 2017. Medifast+1Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health SystemJul 17, 2026Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed DietNCT02835092
What the trial tested
NCT02835092 randomized participants to a self-directed, calorie-reduced diet, the Take Shape For Life coaching program on the Optimal Weight 5 and 1 Plan, or the Medifast Direct program, and measured body weight change at 16 weeks as the registered primary outcome using a digital scale after an overnight fast. Each arm enrolled roughly 65 to 67 participants. The trial posted its results structure to the registry in January 2019, listing body weight change as the sole primary outcome measure, but the materials reviewed here do not carry the disclosed weight-change value or a statistical comparison between arms. NCT02835092Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed DietNCT02835092
The figures Medifast used
The 98% lean-mass retention and 14% visceral-fat reduction figures Medifast is promoting describe body composition, a secondary measure distinct from the trial's registered primary weight-change endpoint. The release additionally states that coach-supported participants lost up to 10 times more weight and 17 times more fat than people trying to lose weight on their own, a relative multiple rather than an absolute effect size. Framing a result as a multiple of a comparator's outcome, without stating either arm's absolute value, is a promotional device the release leans on more than once. MedifastMedifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health SystemJul 17, 2026
Safety and design
The trial's posted adverse-event data show one serious event among 66 at-risk participants in the self-directed control arm, two among 65 in the Take Shape For Life arm, and one among 67 in the Medifast Direct arm, with no deaths reported in any arm. The design was open-label with no blinding, which is standard for a behavioral diet-and-coaching comparison but means neither participants nor coaches were blinded to assignment, a limitation inherent to testing a coaching intervention against a self-directed diet. NCT02835092Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed DietNCT02835092
Where this sits competitively
Medifast's coached-diet model is a behavioral and nutritional intervention, distinct in mechanism from the GLP-1 receptor agonist class now driving late-stage obesity development, including Eli Lilly's tirzepatide and retatrutide and Novo Nordisk's semaglutide and CagriSema, all in Phase 3 or Phase 4 testing for obesity. None of those programs shares Medifast's non-pharmacologic, coaching-based approach, so the two categories are not direct comparators on mechanism, though they compete for the same patient population and outcome, sustained weight loss.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.